Technical Analysis for CNCE - Concert Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 9.46 0.21% 0.02
CNCE closed up 0.21 percent on Monday, April 22, 2019, on 54 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical CNCE trend table...

Date Alert Name Type % Chg
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 0.21%
New 52 Week Low Weakness 0.21%
Wide Bands Range Expansion 0.21%
Oversold Stochastic Weakness 0.21%
New 52 Week Closing Low Bearish -3.86%
Narrow Range Bar Range Contraction -3.86%
New 52 Week Low Weakness -3.86%

Older signals for CNCE ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Concert Pharmaceuticals, Inc., a biotechnology company, develops drug candidates. Its drug candidates address various therapeutic areas, including hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, schizophrenia, multiple tumors, and hyperparathyroidism, as well as provide agents for diabetic nephropathy and other forms of chronic kidney diseases. The company also develops CTP-354, a GABA(A) receptor subtype-selective modulator for the treatment of spasticity and chronic pain. Concert Pharmaceuticals, Inc. has strategic alliances with GlaxoSmithKline plc and Celgene Corporation. The company was founded in 2006 and is based in Lexington, Massachusetts.
Medicine Biotechnology Medical Specialties Life Sciences Pain New Jersey Schizophrenia Chronic Kidney Disease Chronic Pain HIV Tumors Kidney Diseases Celgene Diabetic Nephropathy Bristol Myers Squibb Summit
Is CNCE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 21.0
52 Week Low 9.21
Average Volume 326,104
200-Day Moving Average 14.4457
50-Day Moving Average 13.9358
20-Day Moving Average 11.497
10-Day Moving Average 10.046
Average True Range 0.8213
ADX 37.71
+DI 11.7187
-DI 36.1553
Chandelier Exit (Long, 3 ATRs ) 15.3661
Chandelier Exit (Short, 3 ATRs ) 11.673900000000001
Upper Bollinger Band 14.681
Lower Bollinger Band 8.313
Percent B (%b) 0.18
BandWidth 55.388362
MACD Line -1.3997
MACD Signal Line -1.2442
MACD Histogram -0.1555
Fundamentals Value
Market Cap 214.62 Million
Num Shares 22.7 Million
EPS -2.22
Price-to-Earnings (P/E) Ratio -4.26
Price-to-Sales 4493.13
Price-to-Book 5.70
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.09
Resistance 3 (R3) 10.08 9.85 9.99
Resistance 2 (R2) 9.85 9.69 9.86 9.95
Resistance 1 (R1) 9.66 9.59 9.76 9.67 9.91
Pivot Point 9.43 9.43 9.48 9.44 9.43
Support 1 (S1) 9.24 9.27 9.34 9.25 9.01
Support 2 (S2) 9.01 9.17 9.02 8.97
Support 3 (S3) 8.82 9.01 8.94
Support 4 (S4) 8.83